Lesley M. Foley
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lesley M. Foley has a total of 115 co-authors. Here are the top co-authors by number of shared publications:
- T. Kevin Hitchens
Animal Imaging Center, University of Pittsburgh, Pittsburgh, PA, USA
54 shared publications - Ambika P. Jaswal
Department of Neurological Surgery, UPMC Children’s Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
51 shared publications - Ashok Panigrahy
Department of Radiology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
51 shared publications - Baoli Hu
Department of Neurological Surgery, University of Pittsburgh, Pittsburgh, USA
51 shared publications - Bo Li
Department of Biochemistry
51 shared publications - Carolyn J. Anderson
Department of Chemistry, University of Missouri, Columbia, Missouri
51 shared publications
Latest Publications
- Open Access
- 7 April 2026
- Published by Oxford University Press (OUP) in PNAS Nexus
- Vol. 5  (4) , pgag106
Astrocytic frataxin deficiency drives neurocognitive impairment in sickle cell mice
Individuals with sickle cell disease (SCD) suffer from a high burden of neurocognitive impairment. Cerebrovascular lesions, characterized by diffusion tensor imaging identified neuroaxonal damage, are associated with learning and memory deficits. The molecular and cellular intermediates driving microstructural neuroaxonal damage and cognitive impairment in SCD remain largely unexplored. Herein, we report that sickle cell mice (SS) have reduced expression of frataxin (FXN), a mitochondrial protein, in their astrocytes compared with normal control (AA) mice. A newly generated sickle bone marrow chimeric mouse with astrocyte-specific deletion of FXN (SSFXN-KO) showed worsening white-matter neuroaxonal damage compared with the normal mice lacking astrocytic FXN (AAFXN-KO) as well as with the SS mice with wild-type FXN expression (SSFXN-WT). The SSFXN-KO mice exhibited impaired cognitive function assessed by the functional novel object recognition (NOR) tests. Induction of FXN improved cognitive responses in the SS mice. Overall, our data demonstrate that astrocytic FXN plays a pivotal role in regulating neuroaxonal health and cognitive function in SCD.
- 7 April 2026
- Published by Oxford University Press (OUP) in PNAS Nexus
- Vol. 5  (4) , pgag106
Open AccessAstrocytic frataxin deficiency drives neurocognitive impairment in sickle cell mice
Individuals with sickle cell disease (SCD) suffer from a high burden of neurocognitive impairment. Cerebrovascular lesions, characterized by diffusion tensor imaging identified neuroaxonal damage, are associated with learning and memory deficits. The molecular and cellular intermediates driving microstructural neuroaxonal damage and cognitive impairment in SCD remain largely unexplored. Herein, we report that sickle cell mice (SS) have reduced expression of frataxin (FXN), a mitochondrial protein, in their astrocytes compared with normal control (AA) mice. A newly generated sickle bone marrow chimeric mouse with astrocyte-specific deletion of FXN (SSFXN-KO) showed worsening white-matter neuroaxonal damage compared with the normal mice lacking astrocytic FXN (AAFXN-KO) as well as with the SS mice with wild-type FXN expression (SSFXN-WT). The SSFXN-KO mice exhibited impaired cognitive function assessed by the functional novel object recognition (NOR) tests. Induction of FXN improved cognitive responses in the SS mice. Overall, our data demonstrate that astrocytic FXN plays a pivotal role in regulating neuroaxonal health and cognitive function in SCD.
- Top Cited PapersOpen Access
- 30 May 2025
- Published by Springer Nature in Nature Communications
- Vol. 16  (1) , 1-26
Precision targeting of β-catenin induces tumor reprogramming and immunity in hepatocellular cancers
First-line immune checkpoint inhibitor (ICI) combinations show responses in subsets of hepatocellular carcinoma (HCC) patients. Nearly half of HCCs are Wnt-active with mutations in CTNNB1 (encoding for β-catenin), AXIN1/2, or APC, and demonstrate heterogeneous and limited benefit to ICI due to an immune excluded tumor microenvironment. We show significant tumor responses in multiple β-catenin-mutated immunocompetent HCC models to a novel siRNA encapsulated in lipid nanoparticle targeting CTNNB1 (LNP-CTNNB1). Both single-cell and spatial transcriptomics reveal cellular and zonal reprogramming, along with activation of immune regulatory transcription factors IRF2 and POU2F1, re-engaged type I/II interferon signaling, and alterations in both innate and adaptive immunity upon β-catenin suppression with LNP-CTNNB1 at early- and advanced-stage disease. Moreover, ICI enhances response to LNP-CTNNB1 in advanced-stage disease by preventing T cell exhaustion and through formation of lymphoid aggregates (LA). In fact, expression of an LA-like gene signature prognosticates survival for patients receiving atezolizumab plus bevacizumab in the IMbrave150 phase III trial and inversely correlates with CTNNB1-mutatational status in this patient cohort. In conclusion, LNP-CTNNB1 is efficacious as monotherapy and in combination with ICI in CTNNB1-mutated HCCs through impacting tumor cell-intrinsic signaling and remodeling global immune surveillance, providing rationale for clinical investigations.
- 30 May 2025
- Published by Springer Nature in Nature Communications
- Vol. 16  (1) , 1-26
Top Cited PapersOpen AccessPrecision targeting of β-catenin induces tumor reprogramming and immunity in hepatocellular cancers
First-line immune checkpoint inhibitor (ICI) combinations show responses in subsets of hepatocellular carcinoma (HCC) patients. Nearly half of HCCs are Wnt-active with mutations in CTNNB1 (encoding for β-catenin), AXIN1/2, or APC, and demonstrate heterogeneous and limited benefit to ICI due to an immune excluded tumor microenvironment. We show significant tumor responses in multiple β-catenin-mutated immunocompetent HCC models to a novel siRNA encapsulated in lipid nanoparticle targeting CTNNB1 (LNP-CTNNB1). Both single-cell and spatial transcriptomics reveal cellular and zonal reprogramming, along with activation of immune regulatory transcription factors IRF2 and POU2F1, re-engaged type I/II interferon signaling, and alterations in both innate and adaptive immunity upon β-catenin suppression with LNP-CTNNB1 at early- and advanced-stage disease. Moreover, ICI enhances response to LNP-CTNNB1 in advanced-stage disease by preventing T cell exhaustion and through formation of lymphoid aggregates (LA). In fact, expression of an LA-like gene signature prognosticates survival for patients receiving atezolizumab plus bevacizumab in the IMbrave150 phase III trial and inversely correlates with CTNNB1-mutatational status in this patient cohort. In conclusion, LNP-CTNNB1 is efficacious as monotherapy and in combination with ICI in CTNNB1-mutated HCCs through impacting tumor cell-intrinsic signaling and remodeling global immune surveillance, providing rationale for clinical investigations.
- Open Access
- 11 October 2023
- Published by Elsevier in NeuroImage
- Vol. 282, 120406
Mapping mesoscale connectivity within the human hippocampus
- 11 October 2023
- Published by Elsevier in NeuroImage
- Vol. 282, 120406
Open AccessMapping mesoscale connectivity within the human hippocampus
- Open Access
- 6 July 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 9 from Immuno-PET Imaging of CD69 Visualizes T-Cell Activation and Predicts Survival Following Immunotherapy in Murine Glioblastoma
Pearson's correlation coefficients analysis between immuno-PET signals and survival in ICI and control groups.
- 6 July 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 9 from Immuno-PET Imaging of CD69 Visualizes T-Cell Activation and Predicts Survival Following Immunotherapy in Murine Glioblastoma
Pearson's correlation coefficients analysis between immuno-PET signals and survival in ICI and control groups.
- Open Access
- 6 July 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 10 from Immuno-PET Imaging of CD69 Visualizes T-Cell Activation and Predicts Survival Following Immunotherapy in Murine Glioblastoma
MRI analysis of tumor volume before and after treatment.
- 6 July 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 10 from Immuno-PET Imaging of CD69 Visualizes T-Cell Activation and Predicts Survival Following Immunotherapy in Murine Glioblastoma
MRI analysis of tumor volume before and after treatment.
- Open Access
- 6 July 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Immuno-PET Imaging of CD69 Visualizes T-Cell Activation and Predicts Survival Following Immunotherapy in Murine Glioblastoma
CD69 validation by tissue staining.
- 6 July 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Immuno-PET Imaging of CD69 Visualizes T-Cell Activation and Predicts Survival Following Immunotherapy in Murine Glioblastoma
CD69 validation by tissue staining.
- Open Access
- 6 July 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from Immuno-PET Imaging of CD69 Visualizes T-Cell Activation and Predicts Survival Following Immunotherapy in Murine Glioblastoma
SUV analysis and BioD data of CD69 immuno-PET.
- 6 July 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from Immuno-PET Imaging of CD69 Visualizes T-Cell Activation and Predicts Survival Following Immunotherapy in Murine Glioblastoma
SUV analysis and BioD data of CD69 immuno-PET.
- Open Access
- 6 July 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Immuno-PET Imaging of CD69 Visualizes T-Cell Activation and Predicts Survival Following Immunotherapy in Murine Glioblastoma
CD69 is upregulated upon T-cell activation.
- 6 July 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Immuno-PET Imaging of CD69 Visualizes T-Cell Activation and Predicts Survival Following Immunotherapy in Murine Glioblastoma
CD69 is upregulated upon T-cell activation.
- Open Access
- 6 July 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Immuno-PET Imaging of CD69 Visualizes T-Cell Activation and Predicts Survival Following Immunotherapy in Murine Glioblastoma
CD69 analysis in single-cell RNA-seq data.
- 6 July 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Immuno-PET Imaging of CD69 Visualizes T-Cell Activation and Predicts Survival Following Immunotherapy in Murine Glioblastoma
CD69 analysis in single-cell RNA-seq data.
- Open Access
- 6 July 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Immuno-PET Imaging of CD69 Visualizes T-Cell Activation and Predicts Survival Following Immunotherapy in Murine Glioblastoma
CD69 validation by tissue staining.
- 6 July 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Immuno-PET Imaging of CD69 Visualizes T-Cell Activation and Predicts Survival Following Immunotherapy in Murine Glioblastoma
CD69 validation by tissue staining.